Since MEG3 has recently been shown to regulate the TGF-β signaling pathway in breast cancer cells [8], our data indicate that the combinatorial administration of palbociclib with TGF-β inhibitors (e.g. galunisertib) may be of therapeutic benefit to breast cancer patients. The gene discussed is MEG3; the disease is breast carcinoma.